{"id":"https://openalex.org/W3094645769","doi":"https://doi.org/10.1182/blood-2020-142793","title":"ABL1 Kinase Plays an Important Role in Spontaneous and Melphalan-Induced Genomic Instability in Multiple Myeloma: Potential Therapeutic Application","display_name":"ABL1 Kinase Plays an Important Role in Spontaneous and Melphalan-Induced Genomic Instability in Multiple Myeloma: Potential Therapeutic Application","publication_year":2020,"publication_date":"2020-11-04","ids":{"openalex":"https://openalex.org/W3094645769","doi":"https://doi.org/10.1182/blood-2020-142793","mag":"3094645769"},"language":"en","primary_location":{"id":"doi:10.1182/blood-2020-142793","doi":"https://doi.org/10.1182/blood-2020-142793","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2020-142793","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5103420970","display_name":"Subodh Kumar","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2801671727","display_name":"VA Boston Healthcare System","ror":"https://ror.org/04v00sg98","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1322918889","https://openalex.org/I2799886695","https://openalex.org/I2801671727","https://openalex.org/I4210095851"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Subodh Kumar","raw_affiliation_strings":["Dana Farber Cancer Institute, Boston, MA","VA Boston Healthcare System, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]},{"raw_affiliation_string":"VA Boston Healthcare System, Boston, MA","institution_ids":["https://openalex.org/I2801671727"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112389374","display_name":"Srikanth Talluri","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2801671727","display_name":"VA Boston Healthcare System","ror":"https://ror.org/04v00sg98","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1322918889","https://openalex.org/I2799886695","https://openalex.org/I2801671727","https://openalex.org/I4210095851"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Srikanth Talluri","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA","VA Boston Healthcare System, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]},{"raw_affiliation_string":"VA Boston Healthcare System, Boston, MA","institution_ids":["https://openalex.org/I2801671727"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103176292","display_name":"Jiangning Zhao","orcid":"https://orcid.org/0000-0003-3830-2672","observed_orcids":["https://orcid.org/0000-0003-3830-2672"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jiangning Zhao","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5084310044","display_name":"Chengcheng Liao","orcid":"https://orcid.org/0000-0003-0408-6684","observed_orcids":["https://orcid.org/0000-0003-0408-6684"]},"institutions":[{"id":"https://openalex.org/I2801671727","display_name":"VA Boston Healthcare System","ror":"https://ror.org/04v00sg98","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1322918889","https://openalex.org/I2799886695","https://openalex.org/I2801671727","https://openalex.org/I4210095851"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Chengcheng Liao","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA","VA Boston Healthcare System, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]},{"raw_affiliation_string":"VA Boston Healthcare System, Boston, MA","institution_ids":["https://openalex.org/I2801671727"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5078948384","display_name":"Lakshmi B. Potluri","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2801671727","display_name":"VA Boston Healthcare System","ror":"https://ror.org/04v00sg98","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1322918889","https://openalex.org/I2799886695","https://openalex.org/I2801671727","https://openalex.org/I4210095851"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Lakshmi B. Potluri","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA","VA Boston Healthcare System, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]},{"raw_affiliation_string":"VA Boston Healthcare System, Boston, MA","institution_ids":["https://openalex.org/I2801671727"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5036264384","display_name":"Leutz Buon","orcid":"https://orcid.org/0009-0000-5990-1936","observed_orcids":["https://orcid.org/0009-0000-5990-1936"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Leutz Buon","raw_affiliation_strings":["Dana Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5058738548","display_name":"Shidai Mu","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Shidai Mu","raw_affiliation_strings":["Dana-Farber cancer institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber cancer institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5027257617","display_name":"Jialan Shi","orcid":"https://orcid.org/0000-0001-5642-5436","observed_orcids":["https://orcid.org/0000-0001-5642-5436"]},"institutions":[{"id":"https://openalex.org/I2801671727","display_name":"VA Boston Healthcare System","ror":"https://ror.org/04v00sg98","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1322918889","https://openalex.org/I2799886695","https://openalex.org/I2801671727","https://openalex.org/I4210095851"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jialan Shi","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA","VA Boston Healthcare System, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]},{"raw_affiliation_string":"VA Boston Healthcare System, Boston, MA","institution_ids":["https://openalex.org/I2801671727"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5000397623","display_name":"Mychell A. Neptune","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2801671727","display_name":"VA Boston Healthcare System","ror":"https://ror.org/04v00sg98","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1322918889","https://openalex.org/I2799886695","https://openalex.org/I2801671727","https://openalex.org/I4210095851"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mychell Neptune-Buon","raw_affiliation_strings":["Dana-Farber cancer institute, Boston, MA","VA Boston Healthcare System, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber cancer institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]},{"raw_affiliation_string":"VA Boston Healthcare System, Boston, MA","institution_ids":["https://openalex.org/I2801671727"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110651995","display_name":"Chandraditya Chakraborty","orcid":"https://orcid.org/0009-0004-5865-9593","observed_orcids":["https://orcid.org/0009-0004-5865-9593"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Chandraditya Chakraborty","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5019802024","display_name":"Yu\u2010Tzu Tai","orcid":"https://orcid.org/0000-0001-6199-3569","observed_orcids":["https://orcid.org/0000-0001-6199-3569"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Yu-Tzu Tai","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5041668980","display_name":"Mehmet Samur","orcid":"https://orcid.org/0000-0002-9978-5682","observed_orcids":["https://orcid.org/0000-0002-9978-5682"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mehmet K. Samur","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5062468245","display_name":"Mariateresa Fulciniti","orcid":"https://orcid.org/0000-0002-1432-9742","observed_orcids":["https://orcid.org/0000-0002-1432-9742"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mariateresa Fulciniti","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5056254084","display_name":"RAO H. PRABHALA","orcid":"https://orcid.org/0000-0002-6375-0437","observed_orcids":["https://orcid.org/0000-0002-6375-0437"]},"institutions":[{"id":"https://openalex.org/I2801671727","display_name":"VA Boston Healthcare System","ror":"https://ror.org/04v00sg98","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1322918889","https://openalex.org/I2799886695","https://openalex.org/I2801671727","https://openalex.org/I4210095851"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Rao Prabhala","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA","VA Boston Healthcare System, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]},{"raw_affiliation_string":"VA Boston Healthcare System, Boston, MA","institution_ids":["https://openalex.org/I2801671727"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5063099799","display_name":"Masood A. Shammas","orcid":"https://orcid.org/0000-0002-8932-6829","observed_orcids":["https://orcid.org/0000-0002-8932-6829"]},"institutions":[{"id":"https://openalex.org/I2801671727","display_name":"VA Boston Healthcare System","ror":"https://ror.org/04v00sg98","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1322918889","https://openalex.org/I2799886695","https://openalex.org/I2801671727","https://openalex.org/I4210095851"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Masood A. Shammas","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA","VA Boston Healthcare System, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]},{"raw_affiliation_string":"VA Boston Healthcare System, Boston, MA","institution_ids":["https://openalex.org/I2801671727"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5045740077","display_name":"Nikhil C. Munshi","orcid":"https://orcid.org/0000-0002-7344-9795","observed_orcids":["https://orcid.org/0000-0002-7344-9795","https://orcid.org/0000-0002-8397-100X"]},"institutions":[{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]},{"id":"https://openalex.org/I2801671727","display_name":"VA Boston Healthcare System","ror":"https://ror.org/04v00sg98","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1322918889","https://openalex.org/I2799886695","https://openalex.org/I2801671727","https://openalex.org/I4210095851"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Nikhil C. Munshi","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA","Harvard Medical School, Boston, MA","VA Boston Healthcare System, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]},{"raw_affiliation_string":"Harvard Medical School, Boston, MA","institution_ids":["https://openalex.org/I136199984"]},{"raw_affiliation_string":"VA Boston Healthcare System, Boston, MA","institution_ids":["https://openalex.org/I2801671727"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":3,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":5500,"currency":"USD","value_usd":5500},"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"136","issue":"Supplement 1","first_page":"51","last_page":"51"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10649","display_name":"Multiple Myeloma Research and Treatments","score":0.8330000042915344,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10649","display_name":"Multiple Myeloma Research and Treatments","score":0.8330000042915344,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10123","display_name":"DNA Repair Mechanisms","score":0.15710000693798065,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.0015999999595806003,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/multiple-myeloma","display_name":"multiple myeloma","score":0.9229999780654907},{"id":"https://openalex.org/keywords/abl1-kinase","display_name":"ABL1 kinase","score":0.9909999966621399},{"id":"https://openalex.org/keywords/genomic-instability","display_name":"genomic instability","score":0.6700000166893005},{"id":"https://openalex.org/keywords/homologous-recombination","display_name":"homologous recombination","score":0.9750000238418579},{"id":"https://openalex.org/keywords/rad51","display_name":"RAD51","score":0.8360000252723694},{"id":"https://openalex.org/keywords/melphalan","display_name":"melphalan","score":0.9760000109672546},{"id":"https://openalex.org/keywords/nilotinib","display_name":"nilotinib","score":0.9039999842643738},{"id":"https://openalex.org/keywords/dna-damage-response","display_name":"DNA damage response","score":0.6899999976158142},{"id":"https://openalex.org/keywords/copy-number-alterations","display_name":"copy number alterations","score":0.8040000200271606},{"id":"https://openalex.org/keywords/p53-signaling-pathway","display_name":"p53 pathway","score":0.8199999928474426},{"id":"https://openalex.org/keywords/drug-resistance","display_name":"drug resistance","score":0.6679999828338623},{"id":"https://openalex.org/keywords/micronuclei","display_name":"micronuclei","score":0.6639999747276306},{"id":"https://openalex.org/keywords/single-nucleotide-polymorphism-array","display_name":"single nucleotide polymorphism array","score":0.8090000152587891},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.5979999899864197},{"id":"https://openalex.org/keywords/dna-double-strand-breaks","display_name":"DNA double-strand breaks","score":0.5759999752044678}],"concepts":[{"id":"https://openalex.org/C178169997","wikidata":"https://www.wikidata.org/wiki/Q2892636","display_name":"Genome instability","level":4,"score":0.8949698209762573},{"id":"https://openalex.org/C2779012473","wikidata":"https://www.wikidata.org/wiki/Q3235015","display_name":"RAD51","level":4,"score":0.737931489944458},{"id":"https://openalex.org/C143425029","wikidata":"https://www.wikidata.org/wiki/Q5205747","display_name":"DNA damage","level":3,"score":0.6303352117538452},{"id":"https://openalex.org/C45080847","wikidata":"https://www.wikidata.org/wiki/Q1658004","display_name":"Micronucleus test","level":3,"score":0.5932148694992065},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.5550572276115417},{"id":"https://openalex.org/C2778684742","wikidata":"https://www.wikidata.org/wiki/Q2298283","display_name":"Melphalan","level":3,"score":0.5412421226501465},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.5394850969314575},{"id":"https://openalex.org/C134935766","wikidata":"https://www.wikidata.org/wiki/Q210538","display_name":"DNA repair","level":3,"score":0.5269566178321838},{"id":"https://openalex.org/C102744134","wikidata":"https://www.wikidata.org/wiki/Q22280388","display_name":"Homologous recombination","level":3,"score":0.45138153433799744},{"id":"https://openalex.org/C184235292","wikidata":"https://www.wikidata.org/wiki/Q421851","display_name":"Kinase","level":2,"score":0.447050541639328},{"id":"https://openalex.org/C153911025","wikidata":"https://www.wikidata.org/wiki/Q7202","display_name":"Molecular biology","level":1,"score":0.38020843267440796},{"id":"https://openalex.org/C2776364478","wikidata":"https://www.wikidata.org/wiki/Q467635","display_name":"Multiple myeloma","level":2,"score":0.31882181763648987},{"id":"https://openalex.org/C95444343","wikidata":"https://www.wikidata.org/wiki/Q7141","display_name":"Cell biology","level":1,"score":0.307883083820343},{"id":"https://openalex.org/C552990157","wikidata":"https://www.wikidata.org/wiki/Q7430","display_name":"DNA","level":2,"score":0.2973792850971222},{"id":"https://openalex.org/C54355233","wikidata":"https://www.wikidata.org/wiki/Q7162","display_name":"Genetics","level":1,"score":0.23672175407409668},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.23341649770736694},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.12569791078567505},{"id":"https://openalex.org/C29730261","wikidata":"https://www.wikidata.org/wiki/Q274160","display_name":"Toxicity","level":2,"score":0.07296669483184814},{"id":"https://openalex.org/C178790620","wikidata":"https://www.wikidata.org/wiki/Q11351","display_name":"Organic chemistry","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood-2020-142793","doi":"https://doi.org/10.1182/blood-2020-142793","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2020-142793","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.9391000270843506}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4388900750","https://openalex.org/W2980699639","https://openalex.org/W2980211863","https://openalex.org/W2048888997","https://openalex.org/W2559622157","https://openalex.org/W2979816083","https://openalex.org/W2581763939","https://openalex.org/W2591224296","https://openalex.org/W2987391075","https://openalex.org/W2581533094"],"abstract_inverted_index":{"Dysregulated":[0],"homologous":[1],"recombination":[2],"(HR)":[3],"contributes":[4,50],"to":[5,51,125,147,208,320,335,390,449,501],"the":[6,27,197,225,247,277,293,312,339,351,370,417,426,453,470,528,541,566],"acquisition":[7,313,340,352],"of":[8,13,68,76,128,134,169,178,189,212,227,279,295,304,314,341,353,410,419,428,441,455,475,496,522,530,534,569,631],"genomic":[9,56,94,111,194,220,286,403,559,577,584],"changes":[10],"and":[11,55,93,118,132,152,193,222,233,249,282,302,310,343,381,401,422,432,472,481,489,543,574,579],"development":[12],"drug":[14,575],"resistance":[15],"over":[16],"time":[17],"in":[18,36,58,81,101,137,149,155,158,185,215,252,292,338,405,416,433,452,457,462,510,555,571,589,615,623],"multiple":[19,182,590],"myeloma":[20],"(MM).":[21],"We":[22,39,140,258],"have":[23,259],"now":[24,260],"further":[25],"investigated":[26,232,311,425],"molecular":[28],"intermediates":[29],"that":[30,41,86,108,142,167,203,235,396,520,549],"may":[31],"play":[32,413],"an":[33,460,628],"important":[34],"role":[35,133,226,415,568],"HR":[37,53,91,131,153],"process.":[38,139],"observe":[40,85],"ABL":[42,87],"kinase,":[43],"which":[44],"regulates":[45],"RAD51":[46,150],"through":[47],"its":[48,580],"phosphorylation,":[49],"increased":[52,492,508],"activity":[54,92,154],"instability":[57,95,112,221,404,578],"myeloma.":[59,591],"Moreover,":[60],"Cellular":[61],"response":[62],"after":[63],"DSBs":[64],"involves":[65],"nuclear":[66],"re-localization":[67],"ABL1":[69,77,135,397],"upon":[70],"DNA":[71,186,205,216],"damage.":[72],"A":[73],"cellular":[74],"localization":[75],"has":[78],"been":[79],"confirmed":[80,261],"MM.":[82],"Consistently,":[83],"we":[84,123,231,288,424],"kinase":[88,136],"inhibitor":[89],"reduces":[90,245,399,539],"(as":[96,113],"assessed":[97,114],"by":[98,115,119,163,264,367,465,478,498],"micronucleus":[99],"assay)":[100],"MM":[102,156,254,290,378,388,406,523],"cells.":[103,407,512],"Based":[104],"on":[105,130,285,437,627],"our":[106,518],"observation":[107,519],"melphalan":[109,145,173,238,281,299,333,391,445,490,505,526],"increases":[110],"micronuclei":[116,240,251],"assay":[117],"whole":[120],"genome":[121,420],"sequencing),":[122],"sought":[124],"investigate":[126],"impact":[127,278,427],"melpahalan":[129],"this":[138],"show":[141],"treatment":[143,168,236,371,486,521],"with":[144,172,176,237,332,372,435,444,487,504,517,525],"leads":[146,207],"increase":[148,337,451,461,527],"expression":[151],"cells":[157,171,291,323,385,443,456,477,497,524],"a":[159,209,532],"dose-dependent":[160],"manner.":[161],"Evaluation":[162],"RNA":[164],"sequencing":[165],"showed":[166],"MM1S":[170,442],"is":[174],"associated":[175],"upregulation":[177],"p53":[179],"signaling":[180],"(containing":[181],"genes":[183,213],"involved":[184,214],"damage,":[187],"detection":[188],"damaged":[190],"sites,":[191],"recombination/repair":[192],"instability)":[195],"as":[196,325],"topmost":[198],"pathway.":[199],"These":[200,393,513],"findings":[201],"suggest":[202],"melphalan-induced":[204,402,473,544],"damage":[206,217],"concerted":[210],"overexpression":[211],"response,":[218],"recombination,":[219],"chemoresistance.":[223],"With":[224],"ABL1-kinase":[228,570],"following":[229],"DSB,":[230],"report":[234],"induces":[239],"formation,":[241],"whereas":[242,346],"nilotinib":[243,296,347,373,488,538,550],"significantly":[244,376],"both":[246,305,469,540,572],"basal":[248],"melphlalan-induced":[250],"all":[253],"cell":[255,379,411,438],"lines":[256,380],"tested.":[257],"these":[262,511,563],"observations":[263],"evaluating":[265],"copy":[266,316,354],"number":[267,317,355],"alterations":[268],"using":[269,328],"single":[270],"nucleotide":[271],"polymorphism":[272],"(SNP)":[273],"arrays.":[274,330],"To":[275],"evaluate":[276],"nilotinib,":[280,430],"their":[283],"combination":[284,303,434],"instability,":[287],"cultured":[289],"presence":[294],"(2.5":[297],"\u00b5M),":[298],"(1":[300],"\u00b5M)":[301],"drugs":[306],"for":[307,446],"three":[308],"weeks":[309],"new":[315],"events,":[318,345],"relative":[319],"\"day":[321],"0\"":[322],"(serving":[324],"baseline":[326],"genome),":[327],"SNP":[329],"Treatment":[331,440],"led":[334,448],"massive":[336],"amplification":[342],"deletion":[344],"not":[348],"only":[349],"reduced":[350,468],"events":[356],"under":[357],"spontaneous":[358,400,471,573],"condition":[359],"but":[360],"also":[361,375,491,552],"almost":[362],"completely":[363],"reversed/prevented":[364],"those":[365,502],"induced":[366],"melphlalan.":[368],"Importantly,":[369],"could":[374,582],"sensitized":[377],"bone":[382],"marrow":[383],"plasma":[384],"from":[386],"relapsed":[387],"patients":[389],"treatment.":[392],"data":[394,514,564],"confirm":[395],"inhibition":[398,581],"Since":[408],"components":[409],"cycle":[412],"critical":[414,567],"maintenance":[418],"stability":[421],"growth,":[423],"ABL1-inhibitor":[429],"alone":[431],"melphalan,":[436],"cycle.":[439],"48hrs":[447],"2.5-fold":[450],"accumulation":[454],"S-phase,":[458],"suggesting":[459,507,548],"replication":[463,535,557],"stress":[464,536],"melphalan.":[466],"Nilotinib":[467],"fraction":[474,495],"S-phase":[476],"27%":[479],"(\u00b12%)":[480],"30%":[482],"(\u00b11%),":[483],"respectively.":[484],"Combined":[485],"sub":[493],"G1":[494],"2.3-fold":[499],"compared":[500],"treated":[503],"alone,":[506],"apoptosis":[509],"are":[515],"consistent":[516],"phosphorylation":[529],"RPA32,":[531],"marker":[533],"while":[537,586],"endogenous":[542],"phosphorylated":[545],"RPA32":[546],"level,":[547],"might":[551],"be":[553],"helpful":[554],"combating":[556],"stress-mediated":[558],"instability.":[560],"Taken":[561],"together,":[562],"demonstrate":[565],"(melphalan)-induced":[576],"reduce/delay":[583],"evolution":[585],"enhancing":[587],"cytotoxicity":[588],"Disclosures":[592],"Fulciniti:":[593],"NIH:":[594],"Research":[595],"Funding.":[596],"Munshi:Takeda:":[597],"Consultancy;":[598,600,602,604,606,608,610],"Karyopharm:":[599],"AbbVie:":[601],"Amgen:":[603],"Legend:":[605],"Adaptive:":[607],"Janssen:":[609],"C4:":[611],"Current":[612,620],"equity":[613,621],"holder":[614,622],"private":[616,624],"company;":[617],"OncoPep:":[618],"Consultancy,":[619],"company,":[625],"Membership":[626],"entity's":[629],"Board":[630],"Directors":[632],"or":[633],"advisory":[634],"committees,":[635],"Patents":[636],"&":[637],"Royalties;":[638],"BMS:":[639],"Consultancy.":[640]},"counts_by_year":[],"updated_date":"2026-10-16T09:59:22.235173","created_date":"2020-11-09T00:00:00"}